<?xml version="1.0" encoding="iso-8859-1"?>
<!-- generator="FeedCreator 1.7.2" -->
<rss version="2.0">
    <channel>
        <title>MedWorm Tags: antiretroviral</title>
        <description>MedWorm provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest medical blog items that have been tagged with 'antiretroviral'.</description>
        <link><![CDATA[http://www.medworm.com/rss/search.php?qu=%22antiretroviral%22&t=%22antiretroviral%22&r=Exact&o=d&f=tag]]></link>
        <lastBuildDate>Sat, 03 Sep 2011 02:49:00 +0100</lastBuildDate>
        <item>
            <title>AZT inhibits XMRV</title>
            <link>http://www.medworm.com/index.php?rid=3066735&amp;cid=t_110659_139_f&amp;fid=38879&amp;url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FVirologyBlog%2F%7E3%2FfVPd2Mu0nD4%2F</link>
            <description>Xenotropic murine leukemia virus related virus (XMRV) has been implicated in prostate cancer and chronic fatigue syndrome (CFS). Because XMRV is a retrovirus, it has been suggested that it might be susceptible to some of the many drugs available for treatment of AIDS. Of ten licensed compounds evaluated for activity against XMRV, just one, AZT (azidothymidine), was found to inhibit viral replication.
Compounds used to treat HIV-1 infection fall into distinct classes: protease inhibitors (Ritonavir, Saquinavir, or Indinavir), nucleoside reverse transcriptase inhibitors (NRTI, AZT, 3TC, Tnofovir, D4T), non-nucleoside reverse transcriptase inhibitors (NNRTI, Efavirenz, Nevirapine), integrase inhibitors (118-D-24), and fusion inhibitors (Maraviroc). None of the HIV-1 protease inhibitors, NNRTI...</description>
            <author>virology blog</author>
            <type>blogs</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3066735</comments>
            <pubDate>Tue, 08 Dec 2009 11:00:33 +0100</pubDate>
            <guid isPermaLink="false">3066735</guid>        </item>
        <item>
            <title>Can FDA-Approved HIV Drugs Treat Chemoresistant Ovarian Cancer?</title>
            <link>http://www.medworm.com/index.php?rid=2268014&amp;cid=t_110659_136_f&amp;fid=37846&amp;url=http%3A%2F%2Fhealthinfoispower.wordpress.com%2F2009%2F03%2F15%2Fcan-fda-approved-hiv-drugs-treat-chemoresistant-ovarian-cancer%2F</link>
            <description>Two recent in vitro studies conducted in the U.S. and Europe raise a provocative question:  Can FDA-approved human immunodeficiency virus (HIV) drugs be used to treat chemoresistant ovarian cancer?  Both studies were based upon the fact that HIV patients taking antiretroviral inhibitors have a lower incidence of infection-associated malignancies.  Based upon that fact, the researchers [...] (Source: Libby's H*O*P*E*)</description>
            <author>Libby's H*O*P*E*</author>
            <type>blogs</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2268014</comments>
            <pubDate>Mon, 16 Mar 2009 04:26:23 +0100</pubDate>
            <guid isPermaLink="false">2268014</guid>        </item>
        <item>
            <title>Upper trunk fat. This is not about elephants.</title>
            <link>http://www.medworm.com/index.php?rid=808628&amp;cid=t_110659_87_f&amp;fid=34867&amp;url=http%3A%2F%2Fwww.thediabetesblog.com%2F2007%2F08%2F19%2Fupper-trunk-fat-this-is-not-about-elephants%2F</link>
            <description>This study, linking upper trunk fat to insulin resistance, was conducted by researchers based at the San Francisco VA Medical Center. The connection was actually established in the course of a study of fat redistribution and metabolic change in HIV-infected patients. Both HIV-positive patients on antiretroviral therapy and non-HIV-infected control participants were involved in the study.A surprise finding was this fact that upper trunk fat contributes to insulin resistance just as much as does visceral fat. Also of note: this occurs regardless of whether or not the other type of fat is present. The researchers also note that all study participants were equally at risk. Says lead researcher Dr. Carl Grunfeld, &quot;Strikingly, there was very little difference between HIV-infected people and cont...</description>
            <author>The Diabetes Blog</author>
            <type>blogs</type>
        <comments>http://www.medworm.com/rss/comments.php?id=808628</comments>
            <pubDate>Sun, 19 Aug 2007 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">808628</guid>        </item>
        <item>
            <title>Anti-HIV drug use in pregnancy increases cancer risk</title>
            <link>http://www.medworm.com/index.php?rid=529677&amp;cid=t_110659_87_f&amp;fid=34865&amp;url=http%3A%2F%2Fwww.thecancerblog.com%2F2007%2F04%2F08%2Fanti-hiv-drug-use-in-pregnancy-increases-cancer-risk%2F</link>
            <description>Filed under: All Cancers, Research, Daily newsAntiretroviral drugs, used to prevent HIV transmission from mother to child, are now believed to cause genetic damage in infants. This damage, leading to an increased risk of developing cancer, makes it highly plausible these children may be diagnosed with the disease in mid and late adulthood.Two new studies indicate there are cancer-causing effects of transplacental exposure to AZT, an antiretroviral drug. These effects -- like increased incidence of tumors and tumors with genetic changes -- have been demonstrated in mice and rats and seem to be cause for concern in humans too.&quot;The cumulative mutagenesis data suggest that infants exposed transplacentally to AZT may be at increased risk for cancer as they age,&quot; said one researcher, whose findi...</description>
            <author>The Cancer Blog</author>
            <type>blogs</type>
        <comments>http://www.medworm.com/rss/comments.php?id=529677</comments>
            <pubDate>Sun, 08 Apr 2007 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">529677</guid>        </item>
    </channel>
</rss>

